FDA-cleared profile

Salix Central

Artrya Limited · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Salix Central is a web-based adjunctive tool for qualified professionals to view, post-process, and analyze cardiac CT DICOM images for physician-identified coronary plaque and stenosis assessment and non-contrast calcium scoring.

Clinical role
Cardiac CT post-processing that supports coronary plaque and stenosis review, non-contrast calcium scoring, vessel measurements, and physician reporting.
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: The software is adjunctive, requires qualified professional review, and does not replace clinical judgment. FDA validation was task-specific and regulatory; it does not establish independent clinical outcomes or performance for every scanner, protocol, or later family version.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Salix Central is a web-based adjunctive tool for qualified professionals to view, post-process, and analyze cardiac CT DICOM images for physician-identified coronary plaque and stenosis assessment and non-contrast calcium scoring.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: Cardiac CT DICOM images: contrast CCTA with physician-identified plaque or stenosis and non-contrast cardiac CT for calcium scoring.
  • Who uses it?Intended users: Qualified healthcare professionals reviewing adult cardiac CT; the software is adjunctive and does not replace professional judgment.
  • What does the software produce?Output: Calcium scoring; coronary centerline extraction; vessel labeling; lumen and vessel-wall segmentation; coronary measurements; and a standard coronary report for clinician review.
  • What is its most important limitation?Key limitation: The software is adjunctive, requires qualified professional review, and does not replace clinical judgment. FDA validation was task-specific and regulatory; it does not establish independent clinical outcomes or performance for every scanner, protocol, or later family version.

Clinical takeaway. Clinical role: Salix Central is a web-based adjunctive tool for qualified professionals to view, post-process, and analyze cardiac CT DICOM images for physician-identified coronary plaque and stenosis assessment and non-contrast calcium scoring.

Evidence takeaway. Evidence from the reviewed source record: K243038 FDA evidence is a six-center regulatory validation of Salix Central cardiac CT post-processing; no independent paper or trial was promoted in this timeboxed review.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Salix Central is a web-based adjunctive tool for qualified professionals to view, post-process, and analyze cardiac CT DICOM images for physician-identified coronary plaque and stenosis assessment and non-contrast calcium scoring.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Cardiac CT post-processing that supports coronary plaque and stenosis review, non-contrast calcium scoring, vessel measurements, and physician reporting.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Cardiac CT DICOM images: contrast CCTA with physician-identified plaque or stenosis and non-contrast cardiac CT for calcium scoring.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Calcium scoring; coronary centerline extraction; vessel labeling; lumen and vessel-wall segmentation; coronary measurements; and a standard coronary report for clinician review.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Adult cardiac CT/CCTA interpretation in cardiology or radiology practice.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Qualified healthcare professionals reviewing adult cardiac CT; the software is adjunctive and does not replace professional judgment.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The software is adjunctive, requires qualified professional review, and does not replace clinical judgment. FDA validation was task-specific and regulatory; it does not establish independent clinical outcomes or performance for every scanner, protocol, or later family version.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
K243038 FDA evidence is a six-center regulatory validation of Salix Central cardiac CT post-processing; no independent paper or trial was promoted in this timeboxed review.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K243038 FDA evidence is a six-center regulatory validation of Salix Central cardiac CT post-processing; no independent paper or trial was promoted in this timeboxed review.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Calcium score Pearson correlation

0.958 Pearson correlation coefficient

  • EndpointAgreement of calcium score with reference
  • Population302 non-contrast cardiac CT studies in the validation dataset
  • Tested versionSalix Central configuration described in K243038

Centerline true placement

90.4 percent

  • EndpointCorrect coronary centerline placement
  • Population116 contrast cardiac CT studies in the validation dataset
  • Tested versionSalix Central configuration described in K243038

Lumen-wall segmentation Dice

0.8996 Dice similarity coefficient

  • EndpointAgreement of lumen-wall segmentation with reference
  • Population63 contrast cardiac CT studies in the validation dataset
  • Tested versionSalix Central configuration described in K243038

K243038 Salix Central regulatory validation

  • DesignRetrospective multi-center regulatory validation of calcium scoring, coronary centerline and labeling, and lumen/vessel-wall segmentation against reference results.
  • Population363 unique de-identified cardiac CT studies from six centers across three U.S. states; task-specific sets included 302 non-contrast and 116 contrast studies.
  • Scopeexact submission
  • Tested versionSalix Central configuration described in K243038
  • Samplen=363
  • Sites6
  • IndependenceSponsor or vendor study

K243038

Manufacturer-submitted FDA evidence; it is not an independent clinical-outcome study. The FDA summary's printed confidence interval for vessel-label F1 is internally malformed and was not promoted as a metric.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The wave22 exact-submission recall query returned no native recall record for K243038. This does not establish absence of family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-07
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
Medicare local coverage policy L39881 (Noridian, MAC jurisdictions J-E and J-F) covers AI-enabled coronary plaque analysis from an already completed and interpreted CCTA for stable or acute chest pain with no known coronary disease when the CCTA is intermediate risk or CAD-RADS 1 to 3 and acute coronary syndrome evaluation is negative or inconclusive. It requires FDA cleared or approved software and does not name any product. The related billing article lists CPT 75577 (added effective 2026-01-01, replacing Category III codes 0623T-0626T). This is a regional service-level policy, not a determination that this exact product, version, site or claim is covered or paid. No payment amount was reviewed.
  • Service-level, not product-specific
  • Checked 2026-10-25

75577

Service-level local coverage policy found (Noridian JE/JF LCD L39881); product-specific coverage and payment not established

Medicare (Noridian Healthcare Solutions MACs, jurisdictions J-E and J-F) · Noridian JE and JF states (California, Nevada, Hawaii, American Samoa, Guam, Northern Mariana Islands, Alaska, Arizona, Idaho, Montana, North Dakota, Oregon, South Dakota, Utah, Washington, Wyoming); other MAC jurisdictions not reviewed · Effective 2026-01-01

Code effective date comes from the billing article revision. LCD requires FDA cleared or approved software but names no product. Does not prove eligibility for a particular product version, patient, indication, site or claim; no payment amount reviewed.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Cardiac CT DICOM images: contrast CCTA with physician-identified plaque or stenosis and non-contrast cardiac CT for calcium scoring.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K243038: Salix Central

  2. Routing

    Source context, not route validation: The exact submission accepts cardiac CT DICOM images through a secured network server and stores images; local PACS/RIS routing, identifiers, report delivery, and retention require acceptance testing.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K243038: Salix Central

  3. AI processing

    Source context, not route validation: The FDA packet describes a web-based application using AWS cloud services and a secured network server; it does not establish current hosting region, retention, availability, service-level terms, or the exact deployed cloud configuration.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K243038: Salix Central

  4. Returned objects

    Source context, not route validation: Calcium scoring; coronary centerline extraction; vessel labeling; lumen and vessel-wall segmentation; coronary measurements; and a standard coronary report for clinician review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K243038: Salix Central

  5. Viewer/worklist/report

    Unresolved route: Calcium scoring; coronary centerline extraction; vessel labeling; lumen and vessel-wall segmentation; coronary measurements; and a standard coronary report for clinician review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K243038: Salix Central

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA packet describes a web-based application using AWS cloud services and a secured network server; it does not establish current hosting region, retention, availability, service-level terms, or the exact deployed cloud configuration.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
The exact submission accepts cardiac CT DICOM images through a secured network server and stores images; local PACS/RIS routing, identifiers, report delivery, and retention require acceptance testing.
  • Exact FDA submission
  • Checked 2026-09-07
Training
Use requires qualified professional review of coronary measurements, segmentation, calcium scores, and reports; local onboarding should cover CCTA versus non-contrast inputs, editing, report review, and escalation.
  • Exact FDA submission
  • Checked 2026-09-07
Monitoring
Monitor image eligibility, plaque and stenosis identification, calcium and segmentation edits, report completeness, DICOM delivery, reader overrides, failed or repeated analyses, downtime, updates, complaints, and recalls by exact K243038 release.
  • Exact FDA submission
  • Checked 2026-09-07

Buyer acceptance guidance derived from the exact FDA workflow and validation scope; it is not a claimed vendor monitoring service.

AWS-backed web workflow

The exact FDA submission describes a web-based application using AWS cloud services, secured network-server connectivity, and image storage; confirm the current hosting region, data boundary, retention, and service terms with the vendor.

exact submission · checked 2026-09-07

Artrya Salix family workflow

Artrya's current Salix indication describes a web-based tool for trained professionals that supports cardiac CT plaque, stenosis, and calcium scoring on CT data from any CT scanner as an adjunct to clinical judgment.

product family · checked 2026-09-07

Current family indication; confirm exact K243038 version, scanner compatibility, hosting, licensing, and local interfaces.

Current U.S. identity cross-check

Artrya's investor-relations page identifies Salix Central as the U.S. product cleared under K243038; it does not establish every current family feature or contract term for the cleared configuration.

exact submission · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243038
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-03-27
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor regulatory page, fda device recall, literature index, trial registry, stored candidate metadata, payer policy, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission

    No public list price or contract unit for the exact K243038 configuration was established in the reviewed official sources.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-07 - Exact FDA submission

    The reviewed exact packet and Artrya family pages do not establish current scoped security controls, certification scope, PHI flow, retention, access control, audit, or incident response for K243038.

  • Installation timeline: Not yet reviewed

11 sources - 3 history items

Source ledger

  1. FDA 510(k) K243038: Salix Central

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, integration, deployment, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Salix Central model card (K243038)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Artrya Salix indications for use and user guide entry

    Artrya Limited - Accessed 2026-09-07

    Scope: productFamily, clinicalUse, intendedUsers, limitations, implementationCapabilities

  8. Artrya investor relations: Salix Central USA clearance

    Artrya Limited - Accessed 2026-09-07

    Scope: identity, currentCommercialContext

  9. openFDA exact recall query for K243038

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: postmarketSafety

  10. CMS Medicare Coverage Database LCD L39881: Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaque Analysis (AI-CPA)

    Noridian Healthcare Solutions (MAC jurisdictions J-E and J-F), via CMS Medicare Coverage Database - Accessed 2026-10-25

    Scope: reimbursement, coding, payerPolicy

  11. CMS Medicare Coverage Database Billing and Coding Article A59769: AI-QCT/AI-CPA

    Noridian Healthcare Solutions (MAC jurisdictions J-E and J-F), via CMS Medicare Coverage Database - Accessed 2026-10-25

    Scope: reimbursement, coding, payerPolicy

Research history

  1. K243038 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253786

syngo.CT Coronary Cockpit

Siemens Medical Solutions USA, Inc.

Authorized purpose: An extension for syngo.via that assists trained physicians with automated and semi-automated analysis, visualization and reporting of cardiac CT angiography volume datasets for coronary-lesion evaluation, documentation, follow-up and treatment planning.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2026-06-25
FDA-cleared K260169

AV Cardiac CT

Philips Medical Systems Nederland B.V.

Authorized purpose: AV Cardiac CT assists radiologists, cardiologists and 3D technologists with viewing, processing and analysis of gated cardiac CT data, including coronary anatomy and cardiac function, to prepare cardiac interventions; physician review and decisions remain required.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2026-03-05
FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history